Medivir Gets $14M Milestone as FDA Approves Simeprevir
By Cormac Sheridan
Monday, November 25, 2013
Medivir AB pocketed a €10 million (US$13.5 million) milestone from partner Johnson & Johnson following the FDA approval of its hepatitis C virus (HCV) protease inhibitor (PI) simeprevir, which will be marketed as Olysio.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.